![Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial - The Lancet Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a5af722d-4479-4ef2-9192-4487fdab6f37/gr1.gif)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial - The Lancet
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? | Blood Cancer Journal The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-020-0319-0/MediaObjects/41408_2020_319_Fig1_HTML.png)
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? | Blood Cancer Journal
![Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma | BMC Nephrology | Full Text Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma | BMC Nephrology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12882-018-0962-x/MediaObjects/12882_2018_962_Fig1_HTML.png)
Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma | BMC Nephrology | Full Text
![SciELO - Brasil - Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies Serum free light chain assays not total light chain SciELO - Brasil - Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies Serum free light chain assays not total light chain](https://minio.scielo.br/documentstore/1806-0870/bmKRgcYXXQnRYh8pxk4mj5Q/a9c7257f2b47328ee45b7e9be217c2529e7a6d97.jpg)
SciELO - Brasil - Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies Serum free light chain assays not total light chain
![Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report](https://www.spandidos-publications.com/article_images/ol/12/3/ol-12-03-1884-g02.jpg)
Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
![PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma](https://i1.rgstatic.net/publication/326430488_Serum_free_light_chain_levels_and_renal_function_at_diagnosis_in_patients_with_multiple_myeloma/links/5b4d59a7a6fdcc8dae2468c2/largepreview.png)
PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
![Evidence for Transition From Light Chain Deposition Disease by Immunofluorescence-Only to Classic Light Chain Deposition Disease - Kidney International Reports Evidence for Transition From Light Chain Deposition Disease by Immunofluorescence-Only to Classic Light Chain Deposition Disease - Kidney International Reports](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/3eb6461a-aa0f-4e31-b15c-52e37b516907/gr1.jpg)
Evidence for Transition From Light Chain Deposition Disease by Immunofluorescence-Only to Classic Light Chain Deposition Disease - Kidney International Reports
![Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study | World Journal of Surgical Oncology | Full Text Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1477-7819-12-234/MediaObjects/12957_2014_Article_1912_Fig1_HTML.jpg)
Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study | World Journal of Surgical Oncology | Full Text
![Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria | Scientific Reports Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-94191-8/MediaObjects/41598_2021_94191_Fig1_HTML.png)
Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria | Scientific Reports
![PDF) Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids PDF) Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids](https://i1.rgstatic.net/publication/46220838_Complete_remission_of_lambda_light_chain_myeloma_presenting_with_acute_renal_failure_following_treatment_with_bortezomib_and_steroids/links/5adf754ca6fdcc29358fd00a/largepreview.png)
PDF) Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids
![International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2008.307/MediaObjects/41375_2009_Article_BFleu2008307_Fig1_HTML.jpg)